TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05170230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Description: intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
Study: NCT05808790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive pulmonary metastasectomy
Description: Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.
Study: NCT05123391

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam image guided radiotherapy
Description: Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam image guided radiotherapy
Description: Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)
Study: NCT05264272

Intervention type: OTHER
Intervention: Prospective serological assays
Description: 1. Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~2. BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected.

Intervention type: OTHER
Intervention: Retrospective serological assays
Description: 1. Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~2. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected.
Study: NCT05123391

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam image guided radiotherapy
Description: Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam image guided radiotherapy
Description: Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam image guided radiotherapy
Description: Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam image guided radiotherapy
Description: Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)
Study: NCT06002776

Intervention type: OTHER
Intervention: a retrospective study
Description: a retrospective study
Study: NCT04885400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iJobs
Description: During the program, the participants will learn and exercise successful job search strategies. The web-based adaptation of the Jobs program will allow self-administration. After each session, they will receive written feedback from trainers on the platform.
Study: NCT04578093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARC peer-based curriculum
Description: Peer-based educational videos and supplemental activities
Study: NCT06460610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blow Bottle technique
Description: Patients sit at a table with comfortable position Hold the bottle with one hand and the tube with the other Put the tube in mouth by holding lips firmly Breath in through nose and out through mouth Blowing enough water is bubbled Short Breaks for 2 to 3 mints When mucus rises up get out of it by coughing or huffing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acapella along with Diaphragmatic Breathing
Description: Device which uses a counter weighted plug and magnet to create airway oscillations Acapella combines the effects of PEP therapy and airway vibrations and mobilize to clear pulmonary secretions Facilitates opening of airways in patients with lung disease. Patients instructions to close the mouth piece making surety to no leakage of air. Take a long breath in nose and blow out through the Acapella ,feel vibrations on chest. Duration of performing this technique 3 days a week for 20 mints per day, 4 weeks regular
Study: NCT05537623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Alternatives for Teens and Youths (SAFETY)
Description: Please see description of experimental arm (arm one)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Please see description of active comparator arm (arm two)
Study: NCT05070234

Intervention type: GENETIC
Intervention: Blood collection for genetic analysis
Description: Genetic tests in this study are sequential testing, including MS-MLPA, whole exome sequencing, whole genome sequencing, as well as RNA-seq.
Study: NCT05310747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artwork present
Description: A virtual museum exhibit with a curated selection of artworks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artwork present
Description: A virtual museum exhibit with a curated selection of artworks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artwork absent
Description: The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Artwork absent
Description: The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social connection high
Description: Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social connection high
Description: Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social connection low
Description: Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social connection low
Description: Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
Study: NCT05704777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 24-weeks concurrent exercise training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care
Study: NCT06289686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repairs with BioEnthesis augmentation
Description: Rotator cuff repair using BioEnthesis allograft patch

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repairs without BioEnthesis augmentation
Description: Rotator cuff repair using standard of care sutures and anchors
Study: NCT05691244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Normal Saline
Description: Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovateltide
Description: Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
Study: NCT06658886

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06247072

Intervention type: DEVICE
Intervention: Tonometer
Description: measures IOP

Intervention type: DEVICE
Intervention: Tonometer
Description: measures IOP

Intervention type: DEVICE
Intervention: Tonometer
Description: measures IOP
Study: NCT04956627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Phenytoin Sodium
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Specified dose on specified days
Study: NCT04984681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The control condition will continue receiving usual care or standard of care.
Study: NCT06619886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, engineered T Cells targeting TP53 R248Q
Description: TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle (cycle number N≤3), each cycle was divided into three D0, D7, D14 infusion, a total of 3 dose groups were set up, the single infusion of cells within the range of ±20% all meet the requirements
Study: NCT06174753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg daily X 7 days

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: CMR
Description: CMR 3-5 days post randomization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMR
Description: CMR 3-5 days post randomization
Study: NCT06622954

Intervention type: OTHER
Group type: OTHER
Intervention: Protein- and Calorie restriction
Description: The intervention consists of 30% calorie and 70% protein restriction, based on their daily nutritional intake. The protein and calorie restriction will be given in the form of Scandishake from Nutricia. These are ready available and easy to tailor to the caloric and protein need of each individual study subject.
Study: NCT06619028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted vest
Description: During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
Study: NCT06631326

Intervention type: PROCEDURE
Intervention: hepatic artery infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

Intervention type: DRUG
Intervention: Lenvatinib + PD-1 monoclonal antibody
Description: PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab

Intervention type: DRUG
Intervention: Lenvatinib + PD-1 monoclonal antibody
Description: PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
Study: NCT06718673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual delivery room visit
Description: The real-time labour room demonstration video aims to increase participants' awareness of the labour process, reduce unfamiliarity, and facilitate participation for pregnant women with access restrictions. Produced with a 360-degree camera, it shows detailed sections of the labour room, starting from the entrance. Key areas like birthing beds, toilets, bathrooms, and labour materials (mats, pilates balls, TVs) are highlighted. The video also covers baby cots and rest areas for attendants. Narrated by an experienced midwife, the video ensures patient privacy, no interventions, and excludes images or sounds of other pregnant women. Converted to 360-degree format, the video is available on YouTube for repeated viewing. (https://www.youtube.com/watch?v=EyCt-jTDCVs)

Intervention type: OTHER
Group type: OTHER
Intervention: standart of care
Description: Pregnant women in the control group did not receive any intervention other than routine care and counselling.
Study: NCT06709014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buntanetap/posiphen
Description: 30mg capsule by mouth once daily for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule by mouth once daily for 18 months
Study: NCT06719869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline intravenous catheter
Description: Patients in the intervention group receive a 10 cm PowerGlide Pro™ Midline Catheter (Becton Dickinson). Catheters are inserted with ultrasound-guidance by an anesthesiologist using sterile gloves, mask, and large drape. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. All catheters are secured with using a StatLock™ Stabilization device (Becton Dickinson), and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. Choice of insertion site on arm below or above the elbow avoiding catheter across joints and at the clinician's discretion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Central Venous Catheter (CVC):
Description: Patients in the control group receive a Celsite 320 or 315 (B. Braun) or Pressure Injectable Arrowg+ard Blue Plus+ (Arrow). Catheters are inserted with ultrasound-guidance by an anesthesiologist with maximal sterile precautions (cap, mask, gown, gloves, and large drape) using the Seldinger technique. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. Catheters are secured with monofilament sutures, and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. The choice of insertion site is at the clinician's discretion
Study: NCT06721221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-by-point PVI with the QDot Micro catheter in QMODE+ setting with the Svtag software
Description: PVI will be performed via femoral access after transseptal puncture, guided by fluoroscopy pressure monitoring, intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE). A fast anatomical left atrial map will be created; then, point-by-point PVI will be performed with QDot Micro catheter in QMODE plus with the Svtag software. Inter-tag distance should be ≤ 6 mm on the posterior wall and ≤ 4 mm on the anterior wall. All applications' duration should be 4 seconds. After creating the isolation circle, the presence or absence of first-pass isolation will be assessed on each side by the presence of entrance block. If PVI is complete, this is defined as first-pass isolation. If PVI is not complete at this point, touch-up lesions will be delivered to reach the isolation of all pulmonary veins. After that, acute PV reconnections will be evaluated during a 20 minutes waiting period.
Study: NCT06731244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Patients will be managed as regards their anticoagulant treatment according to usual practice and in accordance with international guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shared decision-making process
Description: The intervention is based on a strategy based on a shared decision-making process which is a collaborative process that involves a patient and their healthcare professional working together to reach a joint decision about care (anticoagulant treatment).~The shared decision-making process will be conducted as follows:~* Step 1: prepare the risk estimates (risk of recurrent VTE, risk of bleeding) for the patient, based on time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI) and other validated risk prediction scores and evidence-based medicine;~* Step 2: Communicating risks, benefits and consequences to the patient;~* Step 3: Make a joint decision about treatment and care, and agree together when this will be reviewed.
Study: NCT06730386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK138D1
Description: Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.
Study: NCT06729996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Description: Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA)
Description: Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.
Study: NCT06731296

Intervention type: OTHER
Intervention: Presence of a risk factor
Description: Demographic, severity, type of surgery, diagnosis, diagnostic system, type of admission.

Intervention type: OTHER
Intervention: Presence of a risk factor
Description: Demographic, severity, type of surgery, diagnosis, diagnostic system, type of admission.
Study: NCT06730737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video preventive education
Description: Interactive video that teaches the subject about the overall importance of prevention, smoking cessation, proper diet, exercise, and sleep.
Study: NCT06731153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivarmacitinib
Description: a selective Janus kinase 1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivarmacitinib
Description: a selective Janus kinase 1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivarmacitinib
Description: a selective Janus kinase 1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (SHR-1210)
Description: a humanised anti-programmed death-1 (anti PD-1) antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (SHR-1210)
Description: a humanised anti-programmed death-1 (anti PD-1) antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.